The Encephalitis drugs in development market research report provides comprehensive information on the therapeutics under development for Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Encephalitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Encephalitis and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Encephalitis by 13 companies/universities/institutes. The top development phase for Encephalitis is preclinical with six drugs in that stage. The Encephalitis pipeline has 13 drugs in development by companies and one by universities/ institutes. Some of the companies in the Encephalitis pipeline products market are: Chengdu Olymvax Biopharmaceuticals, F. Hoffmann-La Roche and UCB.
The key targets in the Encephalitis pipeline products market include Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2), Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2), and Signal Transducer And Activator Of Transcription 3 (Acute Phase Response Factor or DNA Binding Protein APRF or STAT3).
The key mechanisms of action in the Encephalitis pipeline product include B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) Inhibitor with one drug in Phase II. The Encephalitis pipeline products include three routes of administration with the top ROA being Intravenous and six key molecule types in the Encephalitis pipeline products market including Small Molecule, and Monoclonal Antibody.
Encephalitis overview
Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and then travels to brain. Causes include common viruses, childhood viruses, and arboviruses. Risk factors include age and weak immune system. Symptoms include fever, headache, vomiting, stiff neck, coma, and hallucinations. Treatment includes pain killers, corticosteroids, anticonvulsants, and sedatives.
For a complete picture of Encephalitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
